- The USPTO has allowed Provectus' (OTC:PVCT) US patent application 15/804,357 for the combination of intratumoral PV-10 and systemic immunomodulatory therapy for the treatment of a range of solid tumor cancers.
- This prospective new patent is the third continuation of USP 9,107,887, Provectus’ first and foundational cancer combination therapy patent granted by the USPTO in 2015.
- It is also related to USP 9,808,524 and USP 9,839,688, which are also continuations and the Company’s second and third cancer combination therapy patents granted by the USPTO in 2017.
- Pfizer is a co-assignee on all four awarded and allowed patents.
Provectus nabs fourth cancer combination therapy patent in U.S.
Recommended For You
About PVCT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
PVCT | - | - |
Provectus Biopharmaceuticals, Inc. |